Northchip's life sciences board's IPO has been approved, focusing on precision diagnosis and treatment of cardiovascular diseases in Innovative Medical Management equipment production and research and sales.

On July 18th, Shenzhen Beixin Life Science and Technology Co., Ltd. (Beixin Life) had its IPO on the Shanghai Stock Exchange's Sci-Tech Innovation Board approved at a listing committee meeting. The sponsor institution is CICC, with plans to raise 952 million yuan. According to the prospectus, Beixin Life is a national high-tech enterprise specializing in the research, development, production, and sales of precision diagnosis and treatment equipment for cardiovascular diseases. The company is committed to developing innovative solutions that bring revolutionary changes to the diagnosis and treatment of cardiovascular diseases. The company's core products include the intravascular ultrasound (IVUS) diagnostic system, which is China's first domestically developed 60MHz high-definition and high-speed IVUS product approved by the National Medical Products Administration. Beixin Life is the first domestic medical device company in China to have a combination of FFR and IVUS products for intravascular functional study. The company has filled a gap in the domestic market and changed the situation where clinical precise diagnosis of coronary artery disease in China entirely depended on imported products. The company has established a high-performance and high-barrier active intervention medical device product realization system, continuously achieving successful research and development and commercialization of innovative products, gaining recognition in both domestic and international markets and clinical fields. Currently, the company has introduced a total of 11 products to the market, with 6 products in research and development, covering IVUS systems, FFR systems, vascular access products, shockwave balloon treatment systems, and electrophysiological solutions. The company's core IVUS system is China's first domestically developed 60MHz high-definition and high-speed IVUS product with features of high-definition, high-speed, and intelligence, effectively guiding precise PCI strategy development. After deducting issuance expenses, the raised funds will be invested in projects in order of importance. Financially, Beixin Life is expected to achieve operating revenues of approximately 92.45 million yuan, 184 million yuan, and 317 million yuan in the years 2022, 2023, and 2024, respectively. During the same period, the company's net profits are expected to be around -30 million yuan, -15.5 million yuan, and -53.7397 million yuan.